![](https://marengotx.com/wp-content/uploads/2022/04/Orange-T-Cell-small.png)
![](https://marengotx.com/wp-content/uploads/2022/04/Orange-T-Cell.png)
Envision lifelong
protection against
cancer
![](https://marengotx.com/wp-content/uploads/2022/04/3-cell-right-bottom-back.png)
![](https://marengotx.com/wp-content/uploads/2022/04/4-cell-right-bottom-back.png)
![3D render illustration of a blue T cell.](https://marengotx.com/wp-content/uploads/2022/04/5-cell-right-bottom-front.png)
![Female scientist examining the contents of scientific equipment](https://marengotx.com/wp-content/uploads/2023/12/home-about-img.png)
Marengo Therapeutics is pioneering a brand-new way to activate the body’s own immune system to mount a rapid, effective, and durable response against cancer.
As a clinical-stage biotech company, we develop novel TCR-targeting antibodies that selectively modulate common and disease-specific T cell subsets to combat cancer and other diseases.
![Backs of boy and father walking in nature overlayed with blue background.](https://marengotx.com/wp-content/uploads/2022/04/home-approach-bg-image.jpg)
An entirely different approach to tackling cancer with a novel mode of T cell activation
Marengo scientists have discovered a new way to activate specific T cell subsets and fight tumors by directly targeting Variable β (Vβ) chain variants of the TCR. Our first-in-class antibody libraries enable selective modulating of all germline-encoded Vβ TCR variants and therefore support a new way to deploy the human T cell repertoire to fight cancer and other diseases.
![3D render illustration of a T cell attacking a cancer cell](https://marengotx.com/wp-content/uploads/2022/05/home-approach-cell-image-new.png)